2
Clinical Trials associated with [18F]FPyGalA phase 1/2, open-label study to assess safety, tolerability, biodistribution, radiation dosimetry and PET imaging characteristics of [18F]FPyGal in comparison to in vitro diagnostic for the assessment of senescence in oncological patients - SenPET
Start Date28 Apr 2021 |
Sponsor / Collaborator- |
A Phase 1/2, Open-label Study to Assess Safety, Tolerability, Biodistribution, Radiation Dosimetry and PET Imaging Characteristics of [18F]FPyGal in Comparison to in Vitro Diagnostics for the Assessment of Senescence in Oncological Patients
It is of particular interest to find out whether it is possible to use the novel radiotracer [18F]FPyGal to be tested to detect areas after standard tumor therapy that contain resistant (therapy-resistant) tumor cells. This resistance phenomenon in tumor tissues, which may be visualized with the radiotracer [18F]FPyGal, is called tumor senescence.
100 Clinical Results associated with [18F]FPyGal
100 Translational Medicine associated with [18F]FPyGal
100 Patents (Medical) associated with [18F]FPyGal
100 Deals associated with [18F]FPyGal